Hq Specialty Patent-Cliff Exposure & CMS Drug Spending Portfolio

Hq Specialty (US): 4 reconciled FDA prescription therapies, $25.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$25.4M
2024 Medicare Part D Spend$17.5M
2024 Medicaid Spend$7.9M
California HCAI SB 17 Filings1 WAC filings (max 20.5% 2-yr change)